drugset

drugset / Trial / NCT04268069

Efficacy and Safety of PL9643 Ophthalmic Solution in Subjects With Dry Eye

NCT04268069 ↗

Phase 2 Completed 160 enrolled ORA, Inc. Palatin Technologies, Inc · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Evaluation of safety and efficacy of PL9643 Ophthalmic Solution compared to placebo for the treatment of the signs and symptoms of dry eye.

Timeline

Start: 2020-02-14
Primary completion: 2020-10-05
Completion: 2020-10-05

Publications

Evans D, Kenyon K, Ousler G, Watson M, Vollmer P, McLaurin EB, Torkildsen G, Winters J, Dodd J, Jordan R, Wills ST, Spana C. Efficacy and Safety of the Melanocortin Pan-Agonist PL9643 in a Phase 2 Study of Patients with Dry Eye Disease. J Ocul Pharmacol Ther. 2023 Nov;39(9):600-610. doi: 10.1089/jop.2023.0056. Epub 2023 Sep 7.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	PL9643	Unknown	—	Topical

Indications